- Patient with histologically- or cytologically-confirmed colorectal adenocarcinoma with
unresectable or metastatic disease documented on diagnostic imaging studies.
- Patient must have at least one RECIST-defined measurable lesion that has not been
treated with prior local therapy.
- History of another primary malignancy within 3 years prior to study entry, with the
exception of non-melanoma skin cancer and in situ carcinoma of the uterine cervix.
- Current, recent, or planned participation in an experimental treatment drug study
other than this protocol.